


«HEIDELBERG HEALTH ECONOMICS SUMMER SCHOOL»
2024

Bruneck, South Tyrol / Italy
Core Program, September 23-27, 2024

[Introductory Module, September 20/21, 2024]

**New Perspectives for HTA
& Applied Health Economics**

Bridging the Gap between Theory & Practice



The **Heidelberg Health Economics Summer School 2024** is much more than an educational event. Participants will have unique opportunities to interact, debate, and network with a group of preeminent thought leaders in the fields of Health Technology Assessment (HTA) and applied health economic evaluation, at the interface between theory and practice.

For its **Unique Features**, see back cover (p. 20).



University of Heidelberg

International Faculty

- Prof. **Amanda Adler** (Oxford & London, UK)
- Dr. **Richard Baird** (Cambridge, UK)
- Dr. **Meindert Boysen** (London, UK)
- Dr. **Cinzia Brunelli** (Milan, Italy)
- **Thomas B. Cueni** (Geneva, Switzerland)
- Prof. **Sören Holm** (Manchester, UK, & Oslo, Norway)
- Dr. **Mohit Jain** (San Rafael, CA, USA)
- **Christoph Glaetzer** (New Brunswick, NJ, USA)
- Dr. **Kevin Haninger** (Washington, DC, USA)
- Dr. **Ansgar Hebborn** (Basel, Switzerland)
- Dr. **Gergö Merész** (Budapest, Hungary)
- Prof. **Daniel Ollendorf** (Boston, MA, USA)
- Prof. **Maarten Postma** (Groningen, The Netherlands)
- Prof. **Gérard de Pourville** (Paris, France)
- Prof. **Valesca Rétel** (Rotterdam, The Netherlands²)
- Prof. **Jeffrey Richardson** (Melbourne, Vic, Australia)
- Prof. **Michael Schlander** (Heidelberg & Wiesbaden, Germany¹)
- Prof. **Wendelin Schramm** (Heilbronn, Germany²)
- Dr. **Cees Smit** (Amsterdam, The Netherlands)
- Dr. **Oriol de Sola-Morales** (Barcelona, Spain)
- Prof. **Richard Sullivan** (London, UK)

¹Scientific Program Chair; ²*invited*

Guides in Bruneck

- **Christian Tschurtschenthaler** (Bruneck, South Tyrol, Italy³)
- Dr. **Richard Piock** (Bruneck, South Tyrol, Italy⁴)

³Major of the City of Bruneck, 2000-2013

⁴Founder of the *Tyrolean Archive of photographic documentation and art (Tirol Archiv Photographie, TAP)*, and initiator and curator of the exhibition at the LUMEN Museum of Mountain Photography, Kronplatz

Program and Presenting Faculty as at May 25, 2024

– *may be subject to change & revision without notice; [⁴invited]*

Program Overview

Scientific schedule at a glance:

Introductory Module		Core Module				
Friday Sept. 20	Saturday Sept. 21	Monday Sept. 23	Tuesday Sept. 24	Wednesday Sept. 25	Thursday Sept. 26	Friday Sept. 27
	Cost Effectiveness Analysis (II) Modelling Exercises	Health Care Systems & Financing Current Debates	Clinical Effectiveness & Precision Medicine, OMPS, ATMPs	HTA Unresolved Normative & Empirical Issues	Economics Alternatives to the Conventional Paradigm	HTA as Multi-Criteria Decision Analysis?
		[Option for Late Arrival]				
Cost Effectiveness Analysis (I) Valuation Costing Exercises	Decision Analysis	Economic Welfare Theory & The Logic of Cost Effectiveness Current Challenges	HTA Cost Effectiveness & Precision Medicine, OMPS, ATMPs	HTA & Setting Limits Industrial Perspectives Citizens' Perspectives	HTAs Patients' Perspectives Socioeconomic Impact Analysis	Perspectives

© InnoValHC 2024

The scientific **Core Program** will be enhanced by a **Fireside Chat with Thomas Cueni** on Wednesday night, drawing on his rich experience at the interface between health economic evaluations and the real world of decision-making, focusing on the dynamic interaction and interdependence between the international research-based biopharmaceutical industry and political regulation.

Extracurricular program highlights will comprise the official Summer School Welcome Reception at Bruneck Castle on Tuesday night, with **Christian Tschurtschenthaler** also acting as our guide to the **RIPA Messner Mountain Museum** (in Tibetan, ri = mountain, pa = man).

The program of Thursday will take place on top of the Kronplatz summit, with **Richard Piock** offering a guided tour to the **LUMEN Museum of Mountain Photography** during an extended lunch break.

Overview

International Faculty	2
Program Overview	3
Program Objectives	5
Program Characteristics	5
Background & Introduction	7
Core Module	8
Monday: «The Basics / Theoretical Underpinnings»	9
Tuesday: «HTA in Practice»	10
Wednesday: «The Conventional Logic Revisited»	12
Thursday: «The Perspectives of Citizens and Patients»	14
Friday: «Accountability for Reasonableness & Ways Forward»	17
Introductory Module	18
Time Schedule	18
Background Reading Recommendations	18
Further Information, Contact & Application	19
In a Nutshell: Unique Summer School Features	20

Program Objectives

The Health Economics Summer School 2024 will be much more than an educational event. Participants will have unique opportunities to interact, debate, and network with a group of preeminent thought leaders in the fields of Health Technology Assessments (HTAs) and applied health economic evaluation, at the interface between theory and practice.

After attendance, they should be equipped with an overview of and in-depth insights into the most recent evolution of HTA, implications for patient access to new and established medical technologies, covering both those issues that have remained unresolved and those that have newly emerged in the context of new regulation, the rise of precision medicine, and affordable treatment of widespread health problems such as diabetes and obesity.

As a result, attendants will not only have improved their understanding of current systems – criteria and processes – used to regulate the access of patients to health care. Rather they will be on top of the current scientific and policy debate about unresolved issues and how these might be addressed in the future. Thus, they will be prepared to assume active roles in the further evolution of HTAs and the shaping of policies and value frameworks defining the reimbursement and pricing environment for health care interventions.

In order to achieve these objectives, participation will be strictly limited to 30 registered attendants (plus faculty and presenters), resulting in a unique 2:1 ratio between participants and presenting faculty, which will enable intense interaction throughout the Summer School.

Program Characteristics

Intense high-level program

- Core Module – one week
preceded by an optional
- Introductory Module – two-day refresher course

Addressing the most important recent developments
in the worlds of Health Technology Assessment
and health economic evaluation

Practice-orientated with strong theoretical grounding,
combining international policy-relevance with
a state-of-the art high-level scientific program

Experienced international faculty

- ↪ comprised of highly respected thought leaders
in their respective fields, i.e., predominantly,
- ↪ research & development
- ↪ Health Technology Assessment
- ↪ market access, pricing and reimbursement
- ↪ health economics
- ↪ industrial economics
- ↪ medical ethics)

Addressing evaluation issues caused by

- ↪ precision medicine
- ↪ rare and ultra-rare diseases
- ↪ cell and gene therapies
- ↪ innovative cancer combination treatments
- ↪ advanced therapy medicinal products
- ↪ increasingly large target populations (and indication creep)
- ↪ widespread health problems (such as diabetes and obesity)

Discussing the strengths and weaknesses
of the conventional evaluation model in depth

Exploring ways forward how to better integrate

- ↪ social norms and preferences
- ↪ the patients' perspective
- ↪ the citizens' perspective

in Health Technology Assessments (HTAs)

Addressing the missing links between

- ↪ legal and institutional context
- ↪ industrial economics
- ↪ value-based access, pricing, and reimbursement

and how to overcome them

Providing unique opportunities for personal interaction

- with thought-leaders in health economics and HTA,
- including case studies and group exercises,

due to strictly limited number of participants

(30 plus faculty and presenters)

Background & Introduction: Economic Evaluation & Health Technology Assessment (HTA)

The relevance of Health Technology Assessments (HTAs) for market access, pricing and reimbursement of health technologies has increased continuously over the last decades. Conventional HTAs predominantly rest on two pillars:

- an evaluation of clinical effectiveness drawing on well-established principles of evidence-based medicine (EBM),
and
- an attempt to determine the «value for money» offered by interventions using (some sort of) economic assessment.

Yet the approaches adopted by HTA agencies to assess «value for money» vary greatly. This variance can hardly surprise as issues related to access to health care represent an area permeated with ideologically charged controversy.

The «**Heidelberg Health Economics Summer School**» was inaugurated by the not-for-profit *Institute for Innovation & Valuation in Health Care* (InnoVal^{HC}) in 2006 to contribute to closing gaps between the theory and the practice of Health Technology Assessments (HTAs), with or without formal economic evaluation.

A traditional focus has been the systematic appraisal of strengths, weaknesses, limitations, and – on this basis – the appropriate use of economic evaluation methods, ranging from cost benefit analysis (CBA) and cost utility / cost effectiveness analysis (CUA/CEA) to more recently advocated social cost value analysis (SCVA) and variants. Country-specific HTA case studies are used to discuss the policy relevance of these concepts, addressing examples such as the case of orphan medicinal products (OMPs), advanced therapy medicinal products (ATMPs), the evaluation of medical devices and diagnostics, and personalized medicine.

The «**Heidelberg Health Economics Summer School 2024**» has been designed to offer a high-level forum for health care decision makers, health economists, clinician scientists, and advanced PhD students (from academia, independent research institutes, and from the research-based biopharmaceutical industry), to discuss the appropriate role, current use, and limitations of economic evaluations to inform Health Technology Assessments, with a view towards future improvement.

The Summer School will be of particular interest and relevance for specialists in the fields of market access, pricing, reimbursement, clinical research and development, and early value assessment. A key goal is to enable Summer School participants to become well-informed key contributors to the future shaping of the policy environment regulating future patient access to medical innovation.

Core Module: An Intense One-Week Program

On the following pages, the main topics to be addressed will be delineated day by day. All will be illuminated from an economic and social science perspective, supplemented by relevant experience in the real world of policy and decision making.

Structure of the Program

The program will commence with an overview of the contribution of health economics to current debates surrounding the financing of health care. Next, the theory and practice of Health technology Assessments (HTAs) including economic evaluation will be reviewed in-depth.

This will be followed by a closer look at currently discussed options how to better integrate the perspectives (/preferences) of citizens and patients, as a complement or an alternative to the conventional health economic perspectives of society and/or payers.

(a) Monday, September 23, 2024

Monday Presenting Faculty:

Amanda Adler, Ansgar Hebborn, Mohit Jain, Daniel Ollendorf, Jeffrey Richardson, Michael Schlander

09:00am – 06:00pm

The Economics of Health Care Financing

- ↪ International health care systems: how do they compare to each other?
[Or: how should and how can we compare the performance of health care systems?]
- ↪ International health care financing challenges and spending trends
[Can we afford future health care expenditures rising faster than the economies grow?]
- ↪ Health care resource allocation – who should decide?
[Group Exercises & Debate]
- ↪ Agency problems and cost-sharing policies in theory and practice
[What have we learned since the RAND Health Insurance Experiment?]

In case of late arrival on Monday, it will be possible to join the Summer School for the afternoon session without losing flow and context. Please refer also to => «*Application, Registration, Logistics & Support*» at the Institute's *website*.

Health Economic Cost Value Analyses – Theoretical Underpinnings

- ↪ Cost benefit analysis as the theoretical high ground: «*the only game in town*»?
[Economic welfare theory and its application to health(care)]
- ↪ Cost effectiveness analysis – the widely adopted alternative in the context of HTAs
[Premises and promises, current usage and recent developments]
- ↪ Economic theory meeting reality:
[Challenges posed by the evaluation of orphan medicinal products (OMPs), advanced therapy medicinal products (ATMPs), cancer combination treatments, medical devices, diagnostics, and «precision medicine»]

(b) Tuesday, September 24, 2024

Health Technology Assessment (HTA) in International Practice & Experience

Tuesday Presenting Faculty:

Amanda Adler, Richard Baird, Meindert Boysen, Gergö Merész, Mohit Jain, Daniel Ollendorf, Maarten Postma, Gérard de Pouvourville, Jeffrey Richardson, Michael Schlander, Oriol de Sola-Morales

09:00am – 05:30pm

Topics to be addressed:

Pharmaceuticals, including Cancer Combination Treatments, ATMPs, OMPs, Precision Medicine, Companion Diagnostics and Medical Devices, Vaccines, GLP-1 Inhibitors

(i) International Approaches and Experience; Joint Clinical Assessments in Europe

- ↪ England
- ↪ France
- ↪ Germany
- ↪ Hungary
- ↪ The Netherlands
- ↪ Spain
- ↪ European Union
- ↪ United States

(ii) «Technical Issues» in Clinical Effectiveness Assessment

- ↪ Precision medicine, companion diagnostics, and new study designs
- ↪ The missing link between novel research & development strategies and HTA principles

- What are the lessons from the evaluation of OMPs, ATMPs, and cancer combination therapies, if any?

(iii) «Technical Issues» in Cost Effectiveness Analysis

- Health-related quality of life (HRQoL)
- Different ways to measure HRQoL – how do they compare?
- «Utility» and its measurement – impact on evaluation outcomes

(iv) The case of widespread health problems (e.g., diabetes, obesity, Covid-19)

- «Affordability» and budget impact – do they matter?
- «Affordability» and budget impact – should they matter?
- Cost Effectiveness Analysis (CEA) – is it up to the task?
- What are the lessons from the Covid-19 pandemic, if any?

Tuesday Social Event: Summer School Welcome Reception

as of 07:00pm

An evening at Bruneck Castle



Visit of the Bruneck Castle and the «RIPA» Messner Mountain Museum, with its permanent exhibition devoted to the mountain peoples of this world.

Our guide will be **Christian Tschurtschenthaler**, mayor of the City of Bruneck, 2000 – 2013.

The guided tour will be embedded in the Summer School evening reception at the Castle.

(c) Wednesday, September 25, 2024

Wednesday Presenting Faculty:

Sören Holm, Kevin Haninger, Mohit Jain, Daniel Ollendorf, Maarten Postma, Gérard de Pouvourville, Jeffrey Richardson, Michael Schlander, Oriol de Sola-Morales

09:00am – 06:00pm

Topics to be addressed:

«Utility Maximization»; Institutional Context; Social Norms & Preferences; Meanings of «Efficiency»; Industrial Economics & Value-Based Pricing; Setting Limits Fairly; Rarity & OMPs, ATMPs, and «Precision Medicine»

The Logic of Cost Effectiveness – Revisited

- ↪ What are the objectives of collectively financed health schemes?
- ↪ Cost effectiveness and «affordability»
- ↪ In search of «efficiency»
- ↪ Institutional and legal context
- ↪ Social norms and preferences

Contextual Considerations

- ↪ Understanding industrial economics
- ↪ What does it cost to develop a new technology?
- ↪ The need to set limits – how can we approach «fair» pricing and reimbursement?
- ↪ Setting limits and incentives for innovation

The Social Dimension of Health and Health Care

- ↪ «Equity» as an objective:
what should be our primary concern – allocative efficiency or distributive justice?

- The case of OMPs – should we value «rarity»?
- Adopting a citizens' perspective and «social cost value analysis» (SCVA)

Wednesday Special Event: «Fireside Chat» with Thomas B. Cueni

as of 07:30pm

Summer School participants will be invited to a fireside chat with Thomas Cueni.

As the Director General of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) for more than seven years, the long-time Secretary General of Interpharma, the association of pharmaceutical research companies in Switzerland, Secretary of the Biopharmaceutical CEO Round Table (BCR) for 36 years, now recently retired, Thomas Cueni has been a leading biopharmaceutical industry advocate.



Throughout his career, he played a pivotal role in shaping responses to major health crisis, including HIV/AIDS, COVID-19 pandemic and future pandemic preparedness, representing the innovative industry on the WHO ACT-A and the COVAX group. His interest in health systems financing dates back to the early 1990s when, supported by 35 pharma companies, he commissioned the *n/e/r/a* report on Financing Health Care in 12 industrialized countries.

During the evening, he will be available for a candid discussion of the role and limitations of industry shaping the policy environment for fair patient access to medications, including the impact of HTAs and economic evaluation. He will also address prevalent fears that health budgets might be drained by sometimes revolutionary yet unaffordable medical breakthroughs, including advanced cancer treatments, gene and cell therapies. Thomas Cueni is unapologetic about the innovations achieved by the pharmaceutical industry's business model, but he will not shy away from explaining when industry has failed and why. His insights on the black or grey areas of the pharmaceutical industry's failures and shortfalls may not be welcomed by everybody – but facing head-on inconvenient truths is the only way to make progress.

(d) Thursday, September 26, 2024


Thursday Presenting Faculty:

Cinzia Brunelli, Sören Holm, Maarten Postma, Valesca Rétel, Jeffrey Richardson, Michael Schlander, Cees Smit

09:00am – 07:00pm

Topics to be addressed:

Alternatives to the Conventional Paradigm, Social Cost Value Analysis (SCVA), Value Frameworks and Multi-Criteria Decision-Making; Integrating the Patients' Perspective



The scientific program on Thursday will take place at the premises of the LUMEN Museum of Mountain Photography, located on the summit plateau of the Kronplatz mountain (2,275m above sea level; see also below, page 16).

The Search for an Improved or Alternative Evaluation Paradigm

- Do we need alternatives to the conventional «logic of cost effectiveness»?
- Generalized risk-adjusted cost effectiveness analysis («GRACE»)?
- Social cost value analysis («SCVA»)?
- Multi-criteria decision analysis («MCDA»)?
- Value frameworks and «value flowers»

Thursday After-Lunch Event: A Guided Visit to the LUMEN Museum

Lunch at the AlpINN restaurant will be followed by a guided tour at the **LUMEN Museum of Mountain Photography**, which will be offered by **Richard Piock**, an internationally successful entrepreneur with roots in both South and East Tyrol and strong social and intellectual commitment to the area. Among his many initiatives, Richard Piock not only initiated and curated the exhibition of the LUMEN Museum on top of the summit plateau of the Kronplatz, but also the **Tyrolean Archive of photographic documentation and art** (*Tirol Archiv Photographie*, TAP). Beyond its exhibitions, the location offers views of the Messner Mountain Museum MMM Coronas – a fascinating building created by the architect Zaha Hadid (see photograph below) – and spectacular views from the Lienz dolomites in the east to the Ortler in the west.



What about the Perspective of Patients?

- What should be the role of patient-reported outcomes (PROs) in HTA?
[How should we define and measure PROs for the evaluation of health technologies?]
- Is there a place for broader socioeconomic impact of impaired health and health care?
[What about patient preferences that are not strictly “health-related”?]
- The role of patient preferences in economic evaluation
[The different types of preferences and their relationship – individual, selfish / non-selfish, societal, social, citizens’, patients’ preferences]
- How might we better integrate the perspective of patients in cost value analysis?

Roundtable Discussion:

How Viable is the Search for Alternatives?



Venue of the Thursday Sessions

will be the event room of the LUMEN Museum with its breathtaking view over the Alps.

It is located directly adjacent to the exhibition space of the museum (photograph on the left: the famous «shutter», which can be opened and closed and therefore be used as a huge projector screen) and next to the AlpINN restaurant.

For the Summer School participants, a special cable car drive back to Bruneck will be organized as late as at 07:00pm.

(e) Friday, September 27, 2024

Friday Presenting Faculty:

Cinzia Brunelli, Thomas Cueni, Ansgar Hebborn, Sören Holm, Valesca Rétel, Michael Schlander, Cees Smit

09:00am – 03:00pm

Topics to be addressed:

Multi-Criteria Decision-Making; Multi-Stakeholder Consensus Processes; Due Process; Accountability for Reasonableness; Summing Up & Future Perspectives

Health Technology Assessment and Cost Value Analysis

- HTA as multi-criteria decision-making by definition
[formal and informal evaluation criteria; types of evidence; assessment versus «appraisal» of evidence]
- Multi-stakeholder involvement: «SwissHTA» as a case study
[shaping the future of HTA; multi-stakeholder consensus processes]
- Involvement of patients in decision-making – revisited
[types and impacts of patient involvement in assessments and appraisals]
- Due process – evidence-informed deliberation or a black box?

Summing Up

- Which way forward?
- Key challenges – revisited
- What have we learnt?

Introductory Module: An Optional Two-Day Refresher

(f) Friday / Saturday, September 20/21, 2024

For Summer School attendants with relatively little experience or with a little rusty knowledge of health economic evaluation methods, we offer an Introductory Module, which can also be booked separately and independently from the Core Program.

Topics Covered

- ↪ Basics principles of decision analysis
- ↪ Valuation principles in economics
- ↪ Health-adjusted life years
- ↪ Costing in theory and practice
- ↪ Applied cost effectiveness analysis
- ↪ Budget impact analysis
- ↪ Good modeling practice
- ↪ Dealing with uncertainty and sensitivity analyses
- ↪ Exercises and group work

Time Schedule

The core program is scheduled to run on Monday from 9:00am to 6:00pm (with an option to join at 2:00pm in case of late arrival); Tuesday 9:00am to 5:30pm; Wednesday 9:00am to 6:00pm, Thursday 9:00am to 7:00pm, Friday 9:00am to 3:00pm.

Introductory module, Friday 2:00pm to 7:00pm and Saturday 9:00am to 2:00pm.

Selected Background Reading Materials

- ↪ Morris L. Barer et al. (eds.): *Health, Health Care and Health Economics – Perspectives on Distribution*. John Wiley & Sons 1998;
- ↪ John Brazier et al.: *Measuring and Valuing Health Benefits for Economic Evaluation*. Oxford University Press 2017 (2nd edition);

- Glenn Cohen et al.: *Identified versus Statistical Lives. An Interdisciplinary Perspective*. Oxford University Press 2015;
- Norman Daniels and James E. Sabin: *Setting Limits Fairly: Learning to Share Resources for Health*. Oxford University Press 2008 (2nd edition);
- Michael Drummond et al.: *Methods for the Economic Evaluation of Health Care Programs*. Oxford University Press 2015 (4th edition);
- Sherry Glied and Peter C. Smith (eds.): *The Oxford Handbook of Health Economics*. Oxford University Press 2011;
- Marthe Gold et al.: *Cost-Effectiveness in Health and Medicine*. Oxford University Press 1996;
- Daniel M. Hausman and Michael S. McPherson: *Economic Analysis, Moral Philosophy, and Public Philosophy*. Cambridge University Press 2006 (2nd edition);
- Gavin Mooney: *Challenging Health Economics*. Oxford University Press 2009;
- Peter J. Neumann et al. (eds.): *Cost-Effectiveness in Health and Medicine (Second Edition)*. Oxford University Press 2017;
- Peter J. Neumann et al.: *The Right Price: A Value-Based Prescription for Drug Costs*. Oxford University Press 2021;
- Joseph P. Newhouse: *Free for All? Lessons from the RAND Health Insurance Experiment*. Harvard University Press 1994;
- Erik Nord: *Cost-Value Analysis in Health Care. Making Sense out of QALYs*. Cambridge University Press 1999;
- Thomas Rice: *The Economics of Health Reconsidered*. Health Administration Press 2002 (2nd edn.).

Summer School-specific reading materials and case studies are not listed above and will be provided to registered participants.

Further Information & Contact

For **further information regarding the scientific Summer School program**, please contact Professor Michael Schlander at the Institute for Innovation & Valuation in Health Care, An der Ringkirche 4, D-65197 Wiesbaden: michael.schlander@innoval-hc.com.

A comprehensive 52-page report on our previous **Heidelberg Health Economic Summer Schools** – including an **international evaluation** of the most recent program in 2023 – is available as InnoVal^{HC} Discussion Paper No. 36/2023; please see => [here](#) at the Institute's website.

Please see also => **«Application, Registration, Logistics & Support»** at www.innoval-hc.com.

Unique Summer School Features

Interactive. Unique ratio of 2:1 between registered participants and faculty, allowing for interaction facilitated by workshops sessions, exercises, case studies, and roundtable debates

International. Health care policy makers around the world share many fundamental challenges with regard to financing, reimbursement, pricing and access issues, and the appropriate role of Health Technology Assessments (HTAs) including economic evaluation; accordingly, faculty and participants will be from the Americas, Australia, and Europe

Intense. Make no mistake w.r.t. the unparalleled intensity of the scientific program because of the scenic mountain environment and one day on top of the Kronplatz summit; however, we know that some faculty members and some participants plan to have their spouses accompanying them or to add a few days of private vacation once in South Tyrol

In-depth. Key topics (such as handling of OMPs, ATMPs, cancer combination treatments, medical devices, diagnostics and “precision medicine”) will be addressed from more than one perspective, bringing together experts from a variety of relevant backgrounds (including medical ethics, economics, clinical medicine, academia, HTA, and policy makers)

Impartial. The program will be strictly evidence-based and informed by the latest progress in health economics; a clear line will be drawn between facts and opinions, and there will be room for debate and critical review of popular arguments frequently brought forward in debates

Information. The Heidelberg Health Economics Summer Schools were inaugurated by our Institute in 2006; for a review and evaluation of the highly acclaimed programs, see [here](#). For further information, please feel free to contact us by *e mail*

Interested? The program will be most suitable for executives in senior commercial or scientific functions (CEOs, Business Unit Directors, Medical Directors), functions related to patient access (such as health economics), and health policy-makers concerned with HTAs and economic evaluation; it may also be of interest to advanced scholars in the field who wish to actively participate in shaping the future development of the regulatory environment w.r.t. patient access, financing, pricing, and reimbursement policies in the health care sector

To apply for registration, please follow this [link](#). Please contact us for special discounted rates, which are available for a limited number of participants from OECI member institutes, DKFZ/NCT, DKTK, the University of Heidelberg, and local not-for-profit organizations and government agencies in Austria and South Tyrol /Alto Adige.

www.innoval-hc.com